132 related articles for article (PubMed ID: 11812454)
21. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization.
Gelisken F; Inhoffen W; Partsch M; Schneider U; Kreissig I
Am J Ophthalmol; 2001 Apr; 131(4):518-20. PubMed ID: 11292425
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of photodynamic therapy combined with intravitreal triamcinolone acetonide (TA) for treatment of occult choroidal neovascularization secondary to age-related macular degeneration.
Ho TC
Retina; 2006; 26(6):714; author reply 715. PubMed ID: 16829825
[No Abstract] [Full Text] [Related]
23. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
[No Abstract] [Full Text] [Related]
24. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
26. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy.
Ladd BS; Solomon SD; Bressler NM; Bressler SB
Am J Ophthalmol; 2001 Nov; 132(5):659-67. PubMed ID: 11704027
[TBL] [Abstract][Full Text] [Related]
27. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.
Bressler NM; Bressler SB; Haynes LA; Hao Y; Kaiser PK; Miller JW; Naor J; Potter MJ; Pournaras CJ; Reaves A; Rosenfeld PJ; Schmidt-Erfurth U; Slakter JS; Strong A; Vannier S
Arch Ophthalmol; 2005 Sep; 123(9):1283-5. PubMed ID: 16157822
[No Abstract] [Full Text] [Related]
28. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.
Eandi CM; Ober MD; Freund KB; Slakter JS; Yannuzzi LA
Retina; 2007 Sep; 27(7):825-31. PubMed ID: 17891004
[TBL] [Abstract][Full Text] [Related]
29. Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences.
Bressler NM; Bressler SB
Invest Ophthalmol Vis Sci; 2000 Mar; 41(3):624-8. PubMed ID: 10711673
[No Abstract] [Full Text] [Related]
30. Photodynamic therapy for choroidal neovascularization associated with choroidal osteoma.
Battaglia Parodi M; Da Pozzo S; Toto L; Saviano S; Ravalico G
Retina; 2001; 21(6):660-1. PubMed ID: 11756892
[No Abstract] [Full Text] [Related]
31. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.
Soubrane G; Bressler NM
Br J Ophthalmol; 2001 Apr; 85(4):483-95. PubMed ID: 11264143
[No Abstract] [Full Text] [Related]
32. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
[TBL] [Abstract][Full Text] [Related]
33. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: from clinical trials to clinical practice.
Sickenberg M
Semin Ophthalmol; 2001 Dec; 16(4):207-12. PubMed ID: 15513442
[TBL] [Abstract][Full Text] [Related]
34. Photodynamic therapy for inflammatory CNV: do we know enough?
Kramer M
Ocul Immunol Inflamm; 2005; 13(5):331-3. PubMed ID: 16419418
[No Abstract] [Full Text] [Related]
35. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
Kaiser PK;
Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
[TBL] [Abstract][Full Text] [Related]
36. Retinal translocation and photodynamic therapy for age-related macular degeneration with classic choroidal neovascularization: a clinicopathologic case report.
Grossniklaus HE; Brooks HL; Sippy BD; Liu P
Retina; 2002 Dec; 22(6):818-24. PubMed ID: 12476118
[No Abstract] [Full Text] [Related]
37. Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?
Kaiser PK
Br J Ophthalmol; 2010 Feb; 94(2):143-5. PubMed ID: 20139287
[No Abstract] [Full Text] [Related]
38. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
Augustin AJ; Schmidt-Erfurth U
Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
[TBL] [Abstract][Full Text] [Related]
39. Photodynamic therapy with verteporfin for choroidal neovascularization due to age-related macular degeneration and other causes: a New Zealand outcomes study.
Sharp DM; Lai S; Markey CM
Clin Exp Ophthalmol; 2007; 35(1):24-31. PubMed ID: 17300567
[TBL] [Abstract][Full Text] [Related]
40. Photodynamic therapy for choroidal neovascularization in fundus flavimaculatus.
Valmaggia C; Niederberger H; Helbig H
Retina; 2002 Feb; 22(1):111-3. PubMed ID: 11884891
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
